{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:40:57Z","timestamp":1793194857416,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Global Services LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.xjidi.2024.100287","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:10:22Z","timestamp":1717600222000},"page":"100287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-2164","authenticated-orcid":false,"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9741-9067","authenticated-orcid":false,"given":"Patrick J.","family":"Branigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-3067","authenticated-orcid":false,"given":"Xuejun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-6199","authenticated-orcid":false,"given":"Yanqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4195-8616","authenticated-orcid":false,"given":"Samuel","family":"DePrimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-9168","authenticated-orcid":false,"given":"Keying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4647-5303","authenticated-orcid":false,"given":"Brittney","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-416X","authenticated-orcid":false,"given":"Kim","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-157X","authenticated-orcid":false,"given":"Ernesto J.","family":"Mu\u00f1oz-El\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2024.100287_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.immuni.2012.08.024","article-title":"Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria","volume":"37","author":"Basu","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.xjidi.2024.100287_bib2","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.xjidi.2024.100287_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib4","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/jid.2015.144","article-title":"IL-23\/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies","volume":"135","author":"Blauvelt","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib8","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.jaci.2019.01.017","article-title":"Modulation of inflammatory gene transcripts in psoriasis vulgaris: differences between ustekinumab and etanercept","volume":"143","author":"Brodmerkel","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib9","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.4049\/jimmunol.0900036","article-title":"IL-23 drives pathogenic IL-17-producing CD8+ T cells","volume":"182","author":"Ciric","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2024.100287_bib11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"is who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial [published correction appears in Lancet 2020;395:1114]","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2024.100287_bib12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1189\/jlb.0212101","article-title":"Targeting the Th17 pathway in psoriasis","volume":"92","author":"Elloso","year":"2012","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.xjidi.2024.100287_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1203475415584503","article-title":"IL-17A, IL-22, and IL-23 as markers of psoriasis activity: a cross-sectional, hospital-based study","volume":"19","author":"Fotiadou","year":"2015","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.xjidi.2024.100287_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2013.04.028","article-title":"The role of IL-22 and Th22 cells in human skin diseases","volume":"72","author":"Fujita","year":"2013","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.xjidi.2024.100287_bib15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib55","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermtol"},{"key":"10.1016\/j.xjidi.2024.100287_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A\u00a0phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100287_bib17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2024.100287_bib18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/sj.jid.5701067","article-title":"Cellular genomic maps help dissect pathology in human skin disease","volume":"128","author":"Haider","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/jid.2012.456","article-title":"CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-\u03b3, IL-13, IL-17, and IL-22","volume":"133","author":"Hijnen","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib22","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005115","article-title":"The imbalance between Type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris","volume":"13","author":"Kim","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xjidi.2024.100287_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib27","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2024.100287_bib30","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib31","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib32","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100287_bib33","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.immuni.2022.08.007","article-title":"Induction of a colitogenic phenotype in Th1-like cells depends\u00a0on interleukin-23 receptor signaling","volume":"55","author":"Pawlak","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.xjidi.2024.100287_bib34","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/jid.2011.127","article-title":"CCL4L polymorphisms and CCL4\/CCL4L serum levels are associated with psoriasis severity","volume":"131","author":"Pedrosa","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib35","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/gb-2006-7-7-r54","article-title":"Signatures of human regulatory T cells: an encounter with old friends and new players","volume":"7","author":"Pfoertner","year":"2006","journal-title":"Genome Biol"},{"key":"10.1016\/j.xjidi.2024.100287_bib36","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib37","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (Eclipse): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2024.100287_bib38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2024.100287_bib39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100287_bib40","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib41","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/rheumatology\/keab461","article-title":"Interleukin-23 in perspective","volume":"60","author":"Sherlock","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2024.100287_bib42","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1208\/s12248-017-0094-4","article-title":"Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin","volume":"19","author":"Soderstrom","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.xjidi.2024.100287_bib43","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/jid.2010.280","article-title":"Resolved psoriasis lesions retain expression of a subset of disease-related genes","volume":"131","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib45","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/jid.2012.184","article-title":"Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis [published correction appears in J Invest Dermatol 2015;135:2901\u20132]","volume":"132","author":"Su\u00e1rez-Fari\u00f1as","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib46","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.xjidi.2024.100287_bib47","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/jid.2014.261","article-title":"The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells","volume":"134","author":"Teunissen","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044274","article-title":"Meta-analysis derived (MAD) transcriptome of psoriasis defines the \u201ccore\u201d pathogenesis of disease","volume":"7","author":"Tian","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xjidi.2024.100287_bib49","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2013.477","article-title":"Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis","volume":"134","author":"Villanova","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib50","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1038\/jid.2014.216","article-title":"A\u00a0new player on the psoriasis block: il-17A- and IL-22-producing innate lymphoid cells","volume":"134","author":"Ward","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100287_bib51","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/eji.200535503","article-title":"IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis","volume":"36","author":"Wolk","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.xjidi.2024.100287_bib52","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.xjidi.2024.100287_bib53","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00228-016-2110-5","article-title":"First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics\/safety in healthy subjects and patients with moderate-to-severe psoriasis","volume":"72","author":"Zhuang","year":"2016","journal-title":"Eur J Clin Pharmacol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:28:20Z","timestamp":1726446500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026724000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2667026724000341"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100287","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100287"}}